anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, particularly, pediatrics; applicable in antibacterial treatment of mammary glands of women ll with any form of mastitis, various infection and inflammatory diseases after clinical recovery, and practically healthy women with massive microbe dissemination of breast milk. SUBSTANCE: method includes relaxation massage of mammary gland for 3-10 min; applications of suspension of microorganisms of normal microflora of intestine additionally containing 1/8 wt. % of microbiological protective film-forming medium, to region of papilla and areola of mammary gland with exposure for 30-40 min. Medium is used in the form of dry fat-free milk or mixture of lactose, dextran, thiourea and absorbic acid. Preparation is applied in doses ensuring presence of microbic cells in concentration of not less than 10 6  cells per sq.cm of skin. Application of zoobiotics, for instance, bifidumbacterin or lactobacterin is also possible. At the end of treatment mammary gland is subjected to tonic massage. Procedure of sanitation is performed twice a day (in the morning and evening) with course covering 5-7 days. The method provides optimal conditions for production and direct access to excretory ducts and cisterns of mammary glands of multifunctional complex of regulating metabolites possessing sparing effect with respect to conventionally pathogenic microorganisms and nonspecific anabiosis stimulating action on cells of microorganisms in combination with conditions of maximum prolongation of isolation of conventionally pathogenic microorganisms from oxygen at absence of negative action both on organism as a whole, and on microbic homeostasis of feeding mother and baby. EFFECT: higher efficiency. 11 cl, 2 tbl
Technological and implant design advances have helped reduce the frequency of aseptic total joint arthroplasty failure, but periprosthetic joint infections (PJI) remain a clinical important problem with high patient morbidity. Misinterpreting PJI as aseptic mechanical loosening commonly leads to unsatisfactory revision arthroplasty, persistent infection, and poor long-term results. While there is no single "gold standard" diagnostic test for PJI, recent collaborative efforts by Orthopaedic and Infectious Disease Societies have developed algorithms for diagnosing PJI. However, the efficacy of individual tests as well as diagnostic thresholds are controversial. We review the recommended thresholds for commonly used screening tests as well as tissue histopathology and confirmatory tests to diagnose periprosthetic infection. We also update lesser-known laboratory tests, and we briefly summarize rapidly evolving molecular tests to diagnose periprosthetic infection. Pathologists hold a critical role in assisting with PJI diagnosis, maintaining laboratory test quality and interpreting test results. Collaboration between clinicians and pathologists is essential to provide optimal patient care and reduce the burden of PJI.
The present invention relates to dripping pills for treating aphtha and a preparation method thereof. The dripping pills adopt medicinal materials of forsythia, scutellaria root, gardenia, natural indigo, calcined gypsum, pearl layer powder, artificial bezoar, liquorice root, borneol, menthol, polyethyleneglycol-6000, etc. The preparation method comprises the following operation steps: the filter liquor of a plurality of portions of forsythia, scutellaria root, gardenia and liquorice root is extracted by ethanol with the concentration of 50 to 90%; a plurality of portions of natural indigo, calcined gypsum, pearl layer powder and artificial bezoar are added to the filter liquor, and fine powder is obtained; a plurality of portions of menthol and borneol are added to the fine powder; the fine powder is dripped into liquid paraffin by a drip tube, and the dripping pills of the present invention are formed. The present invention has the advantages of simple technology, low cost and easy quality control. The dripping pills of the present invention are suitable for the local medication in the oral cavity, and overcome the defects of easy dispersion and easy dilution of traditional dripping pills, powder preparations, etc., during medication. The dripping pills of the present invention can perform the functions of high efficiency and rapid effect of the medicine.
Fenofibrate tablets, USP are a lipid regulating agent available as tablets for oral administration. Each tablet contains 40 mg or 120 mg fenofibrate. The chemical name for fenofibrate is 2-[4-4-chlorobenzoylphenoxy]-2-methylpropanoic acid 1-methylethyl ester with the following structural formula:

The molecular formula is C20H21ClO4 and the molecular weight is 360.8; fenofibrate is insoluble in water. The melting point is 79° to 82°C. Fenofibrate, USP is a white or almost white crystalline powder which is stable under ordinary conditions. 

Inactive Ingredients: Each tablet contains colloidal silicon dioxide, lactose monohydrate, magnesium stearate, polyethylene glycol, polyoxyl 40 hydrogenated castor oil, povidone, pregelatinized starch (corn), silicified microcrystalline cellulose and vitamin E polyethylene glycol succinate.

Meets USP Dissolution Test 3.
1370980  1,4 - bis - Acylpiperazines BRISTOL-MYERS CO 6 Oct 1972 [7 Oct 1971] 46103/72 Heading C2C Novel 1,4 - bis - acylpiperazines of Formula I in which R and R<SP>1</SP> are independently H or C 1 -C 4  alkyl and X and Y are independently H, alkanoyl having an alkyl group containing up to 20 carbon atoms or C 7 -C 11  aroyl may be prepared (a) by reacting a compound of Formula III wherein R and R<SP>1</SP> are as defined above and Hal is Cl, Br or I with sodium or potassium hydrosulphide, sodium thiocarbonate or with potassium thioloacetate followed by hydrolysis, to obtain a compound of Formula I in which X and Y are hydrogen, (b) by reacting a compound of Formula I in which X and Y are hydrogen with an acylating agent to obtain compounds of Formula I in which X and Y are the same and other than hydrogen, (c) by reacting a compound of Formula II with a sodium or potassium salt of an appropriate alkanoyl or aroyl thioloacid, or (d) by reacting a piperazine having a readily removable blocking group on the 1-nitrogen atom with a haloacyl halide or equivalent acylating agent, converting the resulting 4-haloacyl group into a mercaptoacyl or acylthioester by a process as described above under (a) or (a) and (b), removing the 1-blocking group and forming the desired mercaptoacyl or acylthio group at said 1- position by repeating the above sequence, to obtain a product of Formula I in which Rand R 1  or X and Y are different. Salts of compounds of Formula I in which X and/or Y are/is hydrogen are readily prepared by reaction with a suitable base, e.g. NaOH, Na 2 CO 3 , KOH, KHCO 3 , Ca(OH) 2 , Ba(OH) 2 , Al(OH) 3 , Zn(OH) 2 , triethanolamine, triethylamine, diethylamine, tetramethylammonium hydroxide and benzyltrimethylammonium hydroxide, in a 1 : 1 mole equivalent ratio.  1,4 - bis - (Chloroacetyl)piperazine and 1,4- bis - (2 - chloropropionyl)piperazine may be prepared by reaction of piperazine hexahydrate with the appropriate chloroacylchloride in the presence of sodium bicarbonate. 4 - Chloroacetyl - 1 - formylpiperazine may be prepared by the reaction of 1-formylpiperazine with chloroacetylchloride in water in the presence of sodium bicarbonate. Pharmaceutical compositions having mucolytic activity for oral, parenteral or topical administration in the form of capsules, tablets, solutions or suspensions comprise a compound of Formula I or, when X and Y are H, a salt thereof with a pharmaceutically acceptable base together with an excipient or carrier.
Eighty-one patients were enrolled consecutively over a two-year time period (2014-2015) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 16 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
In the U.S. Registry, a total of 646 individuals received at least one dose of either Ca-DTPA or Zn-DTPA. Of these, 62 received Zn-DTPA by one or more routes of administration. Forty-eight individuals were dosed by intravenous administration, 18 by inhalation and 8 by other or unknown routes of administration.

Of the individuals that received Zn-DTPA, 23/62 (37%) received one dose and 8 (13%) received two doses. The remaining 31 individuals received three or more doses. The largest number of Zn-DTPA doses to a single individual was 574 doses delivered over 3.5 years.

Overall, the presence or absence of adverse events was recorded in 310/646 individuals. Of these 19 (6.1%) individuals reported at least one adverse event. The total number of recorded adverse events was 20. Of the 20 adverse events, 1 individual treated with Zn-DTPA reported headache, lightheadedness, and pelvic pain.

Two individuals experienced cough and/or wheezing with nebulized Ca-DTPA therapy however there was no report of such events with nebulized Zn-DTPA.
Group 3 will consist of healthy aged people defined as in the modified SENIEUR protocol (12, 13). This group is recruited from a previously conducted study. These are community dwelling individuals above the age of 70 and considered as almost healthy with some conditions that are present in the majority of old people such as osteoporosis, osteoarthritis or atherosclerosis.
The invention provides a spermatogenic pill having the functions of warming yang, tonifying kidneys and strengthening the essence. The spermatogenic pill is mainly used for treating azoospermatism. The spermatogenic pill has excellent treatment effect for patients having spermatogenic cells without vas deferens obstruction. The traditional Chinese medicine composition is prepared from the following more than twenty medicinal raw materials by weight: herba epimedii, semen cuscutae, the fruit of Chinese wolfberry, desertliving cistanche, fish glue, goat testicle, male silk moth, human placenta, semen allii tuberose, red ginseng, fleece-flower root, rehmannia glutinosa, rhizoma curculiginis, rhizoma curculiginis, fructus psoraleae, cinnamon, cooked monkshood, angelica sinensis, the root of red-rooted salvia and the like. The spermatogenic pill targets man sterility, has the functions of warming yang, tonifying kidneys and strengthening the essence and is mainly used for treating azoospermatism. The spermatogenic pill can take effect quickly for patients having spermatogenic cells without vas deferens obstruction. Natural Chinese herbal medicines does not have side effects on the body. The formula has the functions of strengthening the essence and effectively increasing the number of sperms.
The invention is a non-viral vesicle vector for the delivery of nucleic acid to various cardiac cell types. The vesicle vector contains the hepatitis B envelope protein wherein at least part of the liver targeting sequence is deleted and replaced with a specific cardiac cell targeting sequence. The targeting sequence may be derived from viruses that have the natural tropism desired (e.g. adenovirus type 5 knob protein for cardiomyocyte delivery) or mammalian sequences (e.g. endothelin-1 for vascular endothelial cell delivery). The vesicle vector contains an expression construct for the expression of therapeutic genes in cardiac tissues.
60 patients will be recruited for this study. After signing the consent form, participant will be randomized to receive usual care (i.e. they will get the current standard care for patients with heart failure) or usual care and participation in the iGetBetter program. Participant will complete a questionnaire in the hospital about their quality of life. iGetBetter group will be given a Bluetooth-equipped scale, blood pressure cuff, and a tablet with a data plan. Participant will check their weight and blood pressure at home daily, using the equipment provided. This information will be sent via the internet to iGetBetter's web server, where the data will be temporarily stored. The data will be monitored by the physician researcher. If their blood pressure is high (e.g. greater than or equal to 140/90 for two days in a row) or they gain a significant amount of weight (e.g. 2 pounds in two days), the study team will be automatically notified. A member of the study team will alert participant cardiologist and the cardiologist will have the option to make any recommendations, such as contacting the subject to schedule an office visit.

Total participation in this study will last 45 days after patient is discharged from the hospital.

Regardless of the assigned group, participant will be asked to complete two questionnaires after 45 days. A member of the research team will contact participant by phone to complete these questionnaires. One of these questionnaires will investigate their quality of life; the other will assess how participant feel the care they have received has affected their health. Patients assigned to the iGetBetter group will also complete a third survey about their satisfaction with the program.
This is a randomized, blinded cross-over study of infants with a diagnosis of Severe BPD that are mechanically ventilated. Participants will receive 3 sets of treatment (2.5mg Albuterol, 1.25mg Albuterol, 3ml normal saline placebo), in random order. Each treatment will be administered every 4 hours for 24 hours. After a 6 hour washout phase, the next group of interventions will be applied. Following another wash-out phase, the final group of intervention will be applied. Pulmonary mechanics from the ventilator (e.g. airway compliance, airway resistance, tidal volume, peak inspiratory pressure, Forced Expiratory Flow at 75% of forced vital capacity, etc.) and the patient short term response to therapy (heart rate, blood pressure, heart rhythm) will be assessed for the duration of the treatment period.
Described herein are methods of treating a disease by treatment with oral sustained release methotrexate alone or in combination with folates. In some embodiments, these approaches improve the pharmacotherapeutic performance of methotrexate therapy. 
     Described herein are novel pharmaceutical compositions for oral administration. Also described herein are novel pharmaceutical compositions for the controlled, sustained delivery of one or more drugs to the stomach or upper gastrointestinal tract. Further described are novel pharmaceutical compositions with increased gastrointestinal residence time. More particularly, novel pharmaceutical compositions which can simultaneously, float in gastric fluid, adhere to the mucosal surfaces of the gastrointestinal tract, swell to a size which delays passage through the pylorus, are described herein. In some embodiments, the pharmaceutical compositions comprise methotrexate. In some embodiments, the pharmaceutical compositions comprise methotrexate and a folate compound. Also described herein are methods for treating or preventing diseases, by administration of the pharmaceutical compositions described herein.
Right ventricular (RV) function is an important prognostic indicator for pulmonary arterial hypertension (PAH), a vasculopathy that primarily and disproportionally affects women with distinct pre- and postmenopausal clinical outcomes. However, most animal studies have overlooked the impact of sex and ovarian hormones on RV remodeling in PAH. Here, we combined invasive measurements of RV hemodynamics and morphology with computational models of RV biomechanics in sugen-hypoxia (SuHx)-treated male, ovary-intact female, and ovariectomized female rats. Despite similar pressure overload levels, SuHx induced increases in end-diastolic elastance and passive myocardial stiffening, notably in male SuHx animals, corresponding to elevated diastolic intracellular calcium. Increases in end-systolic chamber elastance were largely explained by myocardial hypertrophy in male and ovary-intact female rats, whereas ovariectomized females exhibited contractility recruitment via calcium transient augmentation. Ovary-intact female rats primarily responded with hypertrophy, showing fewer myocardial mechanical alterations and less stiffening. These findings highlight sex-related RV remodeling differences in rats, affecting systolic and diastolic RV function in PAH.NEW & NOTEWORTHY Combining hemodynamic and morphological measurements from male, female, and ovariectomized female pulmonary arterial hypertension (PAH) rats revealed distinct adaptation mechanisms despite similar pressure overload. Males showed the most diastolic stiffening. Ovariectomized females had enhanced myocyte contractility and calcium transient upregulation. Ovary-intact females primarily responded with hypertrophy, experiencing milder passive myocardial stiffening and no changes in myocyte shortening. These findings suggest potential sex-specific pathways in right ventricular (RV) adaptation to PAH, with implications for targeted interventions.
OBJECTIVE: Two-sample Mendelian randomization (TSMR) was employed to examine the association between lipidome and five inflammatory skin diseases.
METHOD: To evaluate the association between various molecular subtypes of lipidome and the risk of five inflammatory skin diseases, we analyzed a comprehensive GWAS dataset comprising 179 lipidome. The Two-Sample Mendelian Randomization (TSMR) method was employed to investigate causal relationships. Heterogeneity and pleiotropy were assessed using Cochran's Q test, MR-Egger intercept test, and MR-PRESSO global test. Additionally, a sensitivity analysis was conducted to evaluate the influence of individual single nucleotide polymorphisms on Mendelian Randomization study.
RESULTS: Using 179 serum lipidome as exposures and five common inflammatory skin diseases as outcomes, we investigated their associations in this large-scale study. Our findings reveal significant impacts of glycerophospholipids, glycerolipids, and sphingomyelins on inflammatory skin diseases. Glycerophospholipids were protective against pemphigus but predominantly posed risks for other inflammatory skin diseases. Specifically, phosphatidylcholine (16:0_0:0) exhibited the most significant risk association with lichen planus (OR = 1.25, 95% CI 1.11-1.40, P < 0.001). Conversely, glycerolipids showed no effect on lichen planus but were protective against pemphigus while potentially posing risks for other conditions. Triacylglycerol (46:2) showed the most substantial risk association with vitiligo (OR = 1.99, 95% CI 1.35-2.93, P < 0.001). Furthermore, sphingomyelins had no effect on atopic dermatitis but posed potential risks for other inflammatory skin diseases. Sphingomyelin (d40:1) notably emerged as a significant risk factor for pemphigus (OR = 1.91, 95% CI 1.37-2.66, P < 0.001).
CONCLUSIONS: This study has elucidated the potential harmful effects of glycerophospholipids, glycerolipids, and sphingomyelins on inflammatory skin diseases, while also providing valuable insights for future research into the pathophysiology, prevention and treatment of these conditions.
In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine.
The invention relates to novel ganciclovir (GCV) eye drops or eye gel and a preparation method thereof. The pH (potential of hydrogen) value of a product solution is 6-8. The eye drops or the eye gel comprises 0.1-5% of GCV, 5-30% of sulfobutyl ether-beta-cyclodextrin (SBE-beta-CD), 50-99% of injection water and 0-20% of other additives. The preparation process comprises the following steps: firstly, preparing a soluble compound solution of GCV and SBE-beta-CD, adding (or not adding) a macromolecular thickener (a viscosity modifier) solution containing a pH regulator, an isotonic regulator and a bacteriostat, mixing, performing sterilization, and filtering to obtain the eye drops or the eye gel. The use of SBE-beta-CD can not only improve the dissolubility of GCV but also improve the stability and the permeable cornea absorption of GCV, so that the bioavailability of GCV and the safety of a preparation are improved. Compared with a preparation in the market, the eye drops or the eye gel is relatively safe, stable and efficient.
PURPOSE: The objective of this study was to investigate the efficacy of an artificial intelligence-assisted 3D planning system (AIHIP) in total hip arthroplasty by direct anterior approach and assess the reliability of the AIHIP preoperative program in terms of both interobserver and intraobserver agreement.
METHODS: A retrospective analysis was conducted on patients who underwent unilateral primary THA via direct anterior approach from June 2019 to March 2022. Participants were randomly assigned to receive either the AIHIP system (n = 220) or the 2D template (control group) (n = 220) for preoperative planning. The primary outcome aimed to evaluate the correspondence between the prosthesis selected intro-operation and the one planned preoperatively, as well as to calculate the intraclass correlation coefficient (ICC). Secondary outcomes included operation time, intraoperative blood loss, fluoroscopy times, Harris hip score (HHS), lower limb length difference (LLD), femoral offset (FO), and bilateral femoral offset difference.
RESULTS: No significant differences were observed in gender, age, body mass index (BMI), aetiology, and American Society of Anesthesiologists (ASA) score between the two groups. Both planning methods exhibited good intraobserver agreement for component planning (ICC: 0.941-0.976). Interobserver agreement for component planning was comparable between the two methods (ICC: 0.882-0.929). In the AIHIP group, the accuracy of acetabular cup and femoral stem prosthetics planning significantly improved, with accuracies within the size range of ± 0 and ± 1 being 76.8% and 90.5% and 79.5% and 95.5%, respectively. All differences between two groups were statistically significant (p < 0.05). Patients receiving AIHIP preoperative planning experienced shorter operation times, reduced intraoperative blood loss, fewer fluoroscopy times, and lower leg length discrepancy (LLD) (p < 0.05). Moreover, they demonstrated a higher Harris hip score (HHS) at three days post-surgery (p < 0.05). However, no significant differences were found in femoral offset (FO), difference of bilateral femoral offsets, and HHS at 1 month after the operation.
CONCLUSION: Utilizing AIHIP for preoperative planning of direct anterior approach THA can significantly enhance the accuracy of prosthetic sizing with good reliability, decrease operation time, reduce intraoperative blood loss, and more effectively restore the length of both lower limbs. This approach has greater clinical application value.
The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorder. Accordingly, in one aspect, the present invention provides methods for treating patients with autism spectrum disorder. In one embodiment, a method for treating an autism spectrum disorder (ASD) in a patient comprises the step of administering a therapeutically effective amount of cholesterol to the patient. In more specific embodiments, the ASD is autism, Asperger's disorder, pervasive developmental disorder-not otherwise specified (PDD-NOS), Rett's syndrome and childhood disintegrative disorder. In one embodiment, the patient has autism.